Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA.
Surgery. 2018 May;163(5):1028-1034. doi: 10.1016/j.surg.2017.10.072. Epub 2018 Feb 3.
Orthotopic liver transplantation (OLT) is the preferred treatment for hepatocellular carcinoma (HCC) in select patients. Many patients listed for OLT have a history of prior upper abdominal surgery (UAS). Repeat abdominal surgery increases operative complexity and may cause a greater incidence of complication. This study sought to compare outcomes after liver transplantation for patients with and without prior UAS.
Adult HCC patients undergoing OLT were identified using the database from the Organ Procurement and Transplantation Network (1987-2015). Patients were separated by presence of prior UAS into 2 propensity-matched cohorts. Overall survival (OS) and graft survival (GS) were analyzed by log-rank test and graphed using Kaplan-Meier method. Recipient and donor demographic and clinical characteristics were also studied using Cox regression models.
A total of 15,043 patients were identified, of whom 6,205 had prior UAS (41.2%). After 1:1 propensity score matching, cohorts (UAS versus no UAS) contained 4,669 patients. UAS patients experienced shorter GS (122 months vs 129 months; P < .001) and shorter OS (130 months vs 141 months; P < .001). Median duration of stay for both cohorts was 8 days. Multivariate Cox regression models revealed that prior UAS was associated with an increased hazard ratio (HR) for GS (HR 1.14; 95% confidence interval (CI) 1.06-1.22; P < .001) and OS (HR 1.14; 95% CI 1.06-1.23; P < .001).
Prior UAS is an independent negative predictor of GS and OS after OLT for HCC. OLT performed in patients with UAS remains a well-tolerated and effective treatment for select HCC patients but may alter expected outcomes and influence follow-up protocols.
原位肝移植(OLT)是治疗特定患者肝细胞癌(HCC)的首选方法。许多接受 OLT 治疗的患者都有上腹部手术(UAS)的病史。重复腹部手术会增加手术的复杂性,并可能导致更高的并发症发生率。本研究旨在比较有和无既往 UAS 的患者接受肝移植后的结局。
使用器官获取和移植网络(1987-2015 年)的数据库确定接受 OLT 的 HCC 成年患者。根据是否存在既往 UAS 将患者分为 2 个倾向评分匹配队列。通过对数秩检验分析总生存率(OS)和移植物生存率(GS),并使用 Kaplan-Meier 方法进行绘图。还使用 Cox 回归模型研究了受者和供者的人口统计学和临床特征。
共确定了 15043 例患者,其中 6205 例(41.2%)有既往 UAS。在 1:1 倾向评分匹配后,队列(UAS 与无 UAS)包含 4669 例患者。UAS 患者的 GS(122 个月 vs 129 个月;P<0.001)和 OS(130 个月 vs 141 个月;P<0.001)较短。两个队列的中位住院时间均为 8 天。多变量 Cox 回归模型显示,既往 UAS 与 GS(风险比 1.14;95%置信区间 1.06-1.22;P<0.001)和 OS(风险比 1.14;95%置信区间 1.06-1.23;P<0.001)的风险增加相关。
既往 UAS 是 OLT 治疗 HCC 后 GS 和 OS 的独立负预测因素。在有 UAS 的患者中进行 OLT 仍然是一种可耐受且有效的治疗选择,但可能会改变预期结局并影响随访方案。